drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR-T)
drug_description
Autologous CAR-T cells engineered to recognize CD19 on B-lineage malignancies, inducing T-cell activation and tumor cell lysis in an MHC-independent manner after reinfusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds CD19 on B-lineage tumor cells in an MHC-independent manner, triggering T-cell activation (CD3ΞΆ with costimulatory signaling), cytokine release, proliferation, and cytotoxic killing of CD19-positive cells.
drug_name
CD19-directed CAR-T cells
nct_id_drug_ref
NCT06515626